EMA Recommends a Change to the Terms of the Marketing Authorisation for Mosunetuzumab By Ogkologos - October 23, 2025 114 0 Facebook Twitter Google+ Pinterest WhatsApp It adopted a new route for administration along with a new pharmaceutical form Source RELATED ARTICLESMORE FROM AUTHOR Nivolumab Added to Cisplatin and Radiotherapy Improves DFS in Patients with High-Risk Resected Locally Advanced SCCHN EMA Recommends Granting a Marketing Authorisation for Aumolertinib FDA Approves Niraparib and Abiraterone Acetate Plus Prednisone for BRCA2-mutated Metastatic Castration-Sensitive Prostate Cancer MOST POPULAR ASCO20 Virtual Research Round Up Podcast: Breast Cancer, Sarcoma, and Supportive... July 21, 2020 Cancer in My Community: Working to Expand Access to Clinical Trials... September 22, 2022 FDA Grants Accelerated Approval to Lisocabtagene Maraleucel for Follicular Lymphoma June 3, 2024 Adding 177Lu-PNT2002 to SBRT Significantly Improves PFS in Patients with Oligorecurrent... November 24, 2025 Load more HOT NEWS Efficacy, Safety, and Translational Data from Durvalumab Plus Ceralasertib in Advanced/Metastatic... ESMO Calls for Cancer to Be at the Core of the... FDA Approves Ribociclib with an Aromatase Inhibitor and Ribociclib and Letrozole... Cancer “Decoys” Planted Underneath The Skin Lure In Cancer Cells And...
